FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917256218> ?p ?o ?g. }

• W2917256218 endingPage "1259" @default.
• W2917256218 startingPage "1243" @default.
• W2917256218 abstract "Disease overview The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. Diagnosis Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1500/mm3 and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of morphologic review of the blood and marrow, standard cytogenetics, fluorescent in situ-hybridization, flow immunocytometry, and T-cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic myeloid or lymphoproliferative disorder. Risk stratification Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2016 World Health Organization endorses a semi-molecular classification scheme of disease subtypes which includes the major category “myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2,” and the “MPN subtype, chronic eosinophilic leukemia, not otherwise specified” (CEL, NOS). Lymphocyte-variant hypereosinophilia is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. Risk-adapted therapy The goal of therapy is to mitigate eosinophil-mediated organ damage. For patients with milder forms of eosinophilia (e.g., < 1500/mm3) without symptoms or signs of organ involvement, a watch and wait approach with close-follow-up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Corticosteroids are first-line therapy for patients with lymphocyte-variant hypereosinophilia and HES. Hydroxyurea and interferon-alpha have demonstrated efficacy as initial treatment and steroid-refractory cases of HES. In addition to hydroxyurea, second line cytotoxic chemotherapy agents and hematopoietic cell transplant have been used for aggressive forms of HES and CEL with outcomes reported for limited numbers of patients. The use of antibodies against interleukin-5 (IL-5) (mepolizumab), the IL-5 receptor (benralizumab), and CD52 (alemtuzumab), as well as other targets on eosinophils remains an active area of investigation." @default.
• W2917256218 created "2019-03-02" @default.
• W2917256218 creator A5065621786 @default.
• W2917256218 date "2017-10-17" @default.
• W2917256218 modified "2023-10-14" @default.
• W2917256218 title "World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management" @default.
• W2917256218 cites W110944710 @default.
• W2917256218 cites W15222133 @default.
• W2917256218 cites W1567165257 @default.
• W2917256218 cites W1570200775 @default.
• W2917256218 cites W1663457857 @default.
• W2917256218 cites W1731209109 @default.
• W2917256218 cites W1811953845 @default.
• W2917256218 cites W1890719904 @default.
• W2917256218 cites W1965231759 @default.
• W2917256218 cites W1965564689 @default.
• W2917256218 cites W1965594055 @default.
• W2917256218 cites W1966742864 @default.
• W2917256218 cites W1967766882 @default.
• W2917256218 cites W1967796238 @default.
• W2917256218 cites W1971565434 @default.
• W2917256218 cites W1972031015 @default.
• W2917256218 cites W1972044244 @default.
• W2917256218 cites W1972627918 @default.
• W2917256218 cites W1975966893 @default.
• W2917256218 cites W1977436614 @default.
• W2917256218 cites W1978330466 @default.
• W2917256218 cites W1978563510 @default.
• W2917256218 cites W1978958856 @default.
• W2917256218 cites W1982077238 @default.
• W2917256218 cites W1987362309 @default.
• W2917256218 cites W1989491765 @default.
• W2917256218 cites W1990709019 @default.
• W2917256218 cites W1993099484 @default.
• W2917256218 cites W1994373650 @default.
• W2917256218 cites W1996970629 @default.
• W2917256218 cites W1998721994 @default.
• W2917256218 cites W1999556074 @default.
• W2917256218 cites W2000893535 @default.
• W2917256218 cites W2001533173 @default.
• W2917256218 cites W2002209196 @default.
• W2917256218 cites W2003269232 @default.
• W2917256218 cites W2003567031 @default.
• W2917256218 cites W2004377019 @default.
• W2917256218 cites W2005186531 @default.
• W2917256218 cites W2006432362 @default.
• W2917256218 cites W2006597989 @default.
• W2917256218 cites W2007195093 @default.
• W2917256218 cites W2010463305 @default.
• W2917256218 cites W2012325656 @default.
• W2917256218 cites W2012747721 @default.
• W2917256218 cites W2012952884 @default.
• W2917256218 cites W2013600084 @default.
• W2917256218 cites W2014012322 @default.
• W2917256218 cites W2014433287 @default.
• W2917256218 cites W2015663870 @default.
• W2917256218 cites W2016396075 @default.
• W2917256218 cites W2016712975 @default.
• W2917256218 cites W2017489622 @default.
• W2917256218 cites W2017658844 @default.
• W2917256218 cites W2018110102 @default.
• W2917256218 cites W2019070364 @default.
• W2917256218 cites W2019186253 @default.
• W2917256218 cites W2023071088 @default.
• W2917256218 cites W2023728717 @default.
• W2917256218 cites W2024699324 @default.
• W2917256218 cites W2025690484 @default.
• W2917256218 cites W2029429990 @default.
• W2917256218 cites W2031035248 @default.
• W2917256218 cites W2033319140 @default.
• W2917256218 cites W2033772294 @default.
• W2917256218 cites W2033806960 @default.
• W2917256218 cites W2033967066 @default.
• W2917256218 cites W2035667709 @default.
• W2917256218 cites W2036019382 @default.
• W2917256218 cites W2036047439 @default.
• W2917256218 cites W2038793680 @default.
• W2917256218 cites W2040662490 @default.
• W2917256218 cites W2044327033 @default.
• W2917256218 cites W2047845288 @default.
• W2917256218 cites W2049007536 @default.
• W2917256218 cites W2049357389 @default.
• W2917256218 cites W2050068982 @default.
• W2917256218 cites W2053343706 @default.
• W2917256218 cites W2055961324 @default.
• W2917256218 cites W2057142301 @default.
• W2917256218 cites W2057441293 @default.
• W2917256218 cites W2058240442 @default.
• W2917256218 cites W2061276567 @default.
• W2917256218 cites W2063142212 @default.
• W2917256218 cites W2063548996 @default.
• W2917256218 cites W2064244980 @default.
• W2917256218 cites W2064797674 @default.
• W2917256218 cites W2068757898 @default.
• W2917256218 cites W2071656833 @default.
• W2917256218 cites W2072681676 @default.
• W2917256218 cites W2075213943 @default.
• W2917256218 cites W2075428599 @default.

• next